Scopolamine is the next medication after atropine fails for terminal secretions in hospice patients.
When atropine sulfate is ineffective for controlling death rattle (terminal secretions) in a dying hospice patient, scopolamine 0.4 mg subcutaneously every 4 hours PRN is the recommended next-line agent 1.
Evidence-Based Rationale
The NCCN Palliative Care Guidelines (2016) provide a clear algorithmic approach for managing excessive secretions in patients with weeks of life expectancy. The guideline explicitly lists the following sequence for anticholinergic agents:
- Scopolamine: 0.4 mg subcut every 4 hours PRN, OR 1.5 mg patches (1-3 patches every 3 days)
- Glycopyrrolate: 0.2-0.4 mg IV or subcut every 4 hours PRN (as an alternative)
Both medications are listed as equivalent alternatives after atropine 1.
Key Clinical Considerations
Scopolamine advantages:
- Can be given subcutaneously (practical for hospice setting)
- Available as transdermal patches for sustained effect, though onset is delayed ~12 hours
- Crosses blood-brain barrier (may provide additional sedation, which can be beneficial in actively dying patients)
Glycopyrrolate advantages:
- Does NOT cross blood-brain barrier effectively, reducing delirium risk 1
- May have faster onset than scopolamine in some studies 2
- Produces fewer central anticholinergic side effects
Research Evidence Context
Multiple studies demonstrate equivalence among anticholinergic agents. A randomized trial of 333 patients found atropine, hyoscine butylbromide, and scopolamine equally effective (42%, 42%, and 37% response at 1 hour respectively, P=0.72) 3. Comparative studies show glycopyrrolate may be at least as effective as scopolamine, with some evidence suggesting superior response rates 2, 4.
Practical Implementation
Choose scopolamine if:
- Subcutaneous access is available
- Patient would benefit from mild sedation
- Rapid symptom control needed (use subcutaneous injection, not patch)
Choose glycopyrrolate if:
- Delirium is a concern
- Patient is more alert and you want to minimize central effects
- IV access is readily available
Critical Pitfall
Do NOT use transdermal scopolamine patches as initial therapy when atropine fails in imminently dying patients - the 12-hour onset makes them inappropriate for acute management 1. Use subcutaneous bolus dosing instead, with patches added only for sustained maintenance if the patient survives beyond 24 hours.
If Both Fail
If neither scopolamine nor glycopyrrolate controls secretions, consider octreotide 100-200 mcg subcutaneously every 8 hours as third-line therapy 1. This somatostatin analog reduces secretion production through a different mechanism and is particularly useful for refractory cases.